Just before the holidays, the Swedish government published its new life science strategy. It describes eight prioritized areas that will strengthen the industry and contribute to Sweden’s…
The Oncorena company presented at the Park Annual meeting September 2014 by the CEO Jan Tornell. This future treatment is intended for patients with advanced kidney cancer.
The active phase of LIDDS´ second phase IIa-study with Liproca® Depot has been completed successfully
The treatment of all 18 patients with localized prostate cancer in LIDDS´ second phase IIa-study with its first product Liproca® Depot has now been completed and the evaluation of the results has been initiated. A final version of the report is expected in October 2013.
PULS’s Head of Business Development, Maria Forss, is one of the 200 women selected by Maud Olofsson, the Minister for Enterprise and Energy, in collaboration with ALMI Företagspartner, to participate in the Styrelsekraft program. This is a national mentoring program targeting qualified and experienced women who have the ambition to be board members of both private and public companies